Given the laborious and costly nature of identifying clinically actionable alterations in the member genes of the Myc and RTK-RAS pathways, we intended to develop a classifier that could accurately identify PAAD with greater clinical relevance. This evidence concerns the gene MYC and pancreatic adenocarcinoma.